Diagnosis and treatment of a hepatocellular carcinoma;Diagnostik und Therapie des hepatozellulären Karzinoms

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 8, 2004, Pages 368-372

  Spangenberg, H C ^a   Zuber Jerger, I ^a   Mohr, L ^a   Thimme, R ^a   Blum, H E ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA INTERFERON; CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; LIPID; MITOMYCIN C; OCTREOTIDE; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIMIDINE ANTAGONIST; SOMATOSTATIN RECEPTOR; TAMOXIFEN;

ALCOHOLISM; ANTIANGIOGENIC ACTIVITY; CHEMOTHERAPY; CLINICAL PRACTICE; GENE THERAPY; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; LIVER CELL CARCINOMA; PATHOGENESIS; REVIEW; RISK; SCREENING; SURGICAL TECHNIQUE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; ETHANOL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MASS SCREENING; NEOPLASM STAGING;

EID: 1442323592     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-819893     Document Type: Review

References (16)

1. Allgaier H-P, Deibert P, Olschewski M et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer 1998; 79: 601-605
2. Befeler AS, di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619
3. Bruix J, Llovett JM. HCC surveillance: who is the target population? Hepatology 2003; 37: 507-509
4. Chan CJ, Chow PK, Tai BC et al. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. The Cochrane Library, Oxford, 2002: 4
5. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-891
6. Lau WY, Leung TW, Ho SK et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801
7. Llovett JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC Staging clssification. Semin Liv Dis 1999; 19: 329-338
8. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
9. Marrero JA, Su GL, Wie W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121
10. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treament for small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
11. Nagashima I, Hamada C, Naruse K et al. Surgical resection for small hepatocellular carcinoma. Surgery 1996; 119: 40-45
12. Nakamoto Y, Guidotti LG, Kuhlen CF et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350
13. Santagostino E, Colombo M, Rivi M et al. Six-month versus 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102: 78-82
14. Thorgeirsson SS. Hunting for tumor suppressor genes in liver cancer. Hepatology 2003; 37: 739-741
15. Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-527
16. von Weizsäcker F, Allgaier HP, Blum HE. Prävention des hepatozellulären Karzinoms. Schweiz Rundsch Med Prax 2002; 91: 1393-1395